Aliskiren vs. angiotensin receptor blockers in hypertension: Meta-analysis of randomized controlled trials

American Journal of Hypertension

Volumn 24, Issue 5, 2011, Pages 613-621

  Gao, Dengfeng ^a,b   Ning, Ning ^a   Niu, Xiaolin ^a,b   Wei, Jin ^a   Sun, Ping ^a   Hao, Guanghua ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

angiotensin receptor blockers; blood pressure; hypertension; meta analysis; renin inhibitor

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; BLOOD PRESSURE; FUMARATES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79954738606     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2011.3     Document Type: Article

References (28)

1. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary he the Framingham Study. 1969. Chest 2009; 136:e23.
2. Vongpatanasin W. Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction. J Clin Hypertens (Greenwich) 2007; 9:11-15.
3. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45:907-913. (Pubitemid 40628936)
4. Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol 2010; 105:10A-20A.
5. Mancia G. Annattasio C, Seravalle G, Quarti-Trevano F, Grassi G. Protective effects of renin-angiotensin blockade beyond blood pressure control. J Hum Hypertens 2009; 23:570-577.
6. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005; 16:592-599. (Pubitemid 41725095)
7. Kelly DJ, Wilkinson-Berka JL, Gilbert RE. Renin inhibition: new potential for an old therapeutic target. Hypertension 2005; 46:471-472. (Pubitemid 41376821)
8. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lo acy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2008: CD007066.
9. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev 2007: MR000010.
10. Jadad AR, Moore RA, Carroll D Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12. (Pubitemid 26120810)
11. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
12. Higgins JPT, Green S, Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell: Chichester, England; Hoboken, NJ, 2008.
13. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42:1137-1143 (Pubitemid 37549068)
14. A randomized, double-blind, placebo and active-controlled, multicenter, parallel-group study comparing SPP100(Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. http://www.novctrd.com/ctrdWebApp/ clinicaltrialrepository/displayFile.do?trialResult=2494.
15. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11-20. (Pubitemid 46014059)
16. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221-229. (Pubitemid 47069535)
17. Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z Zhang J. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients ot adequately responsive to hydrochlorothiazide alone. J Clin Hypertens G24-332.
18. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24:93-103.
19. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111:1012-1018. (Pubitemid 40354519)
20. Krone W, Hanefeld M, Meyer HF, Jung T, Bartlett M, Yeh CM, Rajman I, Prescott MF, Dole WP. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2010.
21. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49:1047-1055. (Pubitemid 351664315)
22. Persson F, Rossing P Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32:1873-1879.
23. Yusuf S, Teo KK, Pogue J, Dya L, Copland I, Schumacher H, Dagenais G, Sleight P Anderson C; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. (Pubitemid 351522739)
24. Jackson JH, Sobolski J, Krienke R, Wong KS, Frech-Tamas F, Nightengale B. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines. J Am Board Fam Med 2008; 21:512-521.
25. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119:530-537.
26. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446. (Pubitemid 351793017)
27. Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure (ATMOSPHERE). Identifier: NCT00853658. Error! Hyperlink reference not valid. Accessed 20 May 2010.
28. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24:1663-1671.